228 related articles for article (PubMed ID: 27806410)
1. To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib.
Waidmann O; Peveling-Oberhag J; Eichler K; Schulze F; Vermehren J
Z Gastroenterol; 2017 Jun; 55(6):564-568. PubMed ID: 27806410
[No Abstract] [Full Text] [Related]
2. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
[TBL] [Abstract][Full Text] [Related]
3. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Lim S; Han J; Kim GM; Han KH; Choi HJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
[TBL] [Abstract][Full Text] [Related]
5. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
6. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
9. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
11. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Hagihara A; Teranishi Y; Kawamura E; Fujii H; Iwai S; Morikawa H; Enomoto M; Tamori A; Kawada N
Intern Med; 2013; 52(14):1589-92. PubMed ID: 23857091
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
13. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
Lu LC; Chen PJ; Yeh YC; Hsu CH; Chen HM; Lai MS; Shao YY; Cheng AL
Anticancer Res; 2017 May; 37(5):2593-2599. PubMed ID: 28476832
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Kudo M
Oncology; 2011; 81 Suppl 1():50-5. PubMed ID: 22212936
[TBL] [Abstract][Full Text] [Related]
15. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
Beste LA; Green PK; Berry K; Kogut MJ; Allison SK; Ioannou GN
J Hepatol; 2017 Jul; 67(1):32-39. PubMed ID: 28267622
[TBL] [Abstract][Full Text] [Related]
17. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Cabrera R; Limaye AR; Horne P; Mills R; Soldevila-Pico C; Clark V; Morelli G; Firpi R; Nelson DR
Aliment Pharmacol Ther; 2013 Jan; 37(1):91-7. PubMed ID: 23094860
[TBL] [Abstract][Full Text] [Related]
18. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Maida M; Macaluso FS; Valenza F; Virdone R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
[TBL] [Abstract][Full Text] [Related]
19. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Liu D; Liu A; Peng J; Hu Y; Feng X
Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
[TBL] [Abstract][Full Text] [Related]
20. Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Moroni M; Zanlorenzi L
Future Oncol; 2013 Aug; 9(8):1231-7. PubMed ID: 23902251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
